Cargando…

Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study

BACKGROUND: Indacaterol is a novel, once-daily (o.d.) inhaled, long-acting β(2)-agonist in development for chronic obstructive pulmonary disease (COPD). This 12-week, double-blind study compared the efficacy, safety, and tolerability of indacaterol to that of placebo in patients with moderate-to-sev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feldman, Gregory, Siler, Thomas, Prasad, Niyati, Jack, Damon, Piggott, Simon, Owen, Roger, Higgins, Mark, Kramer, Benjamin
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848004/ https://www.ncbi.nlm.nih.gov/pubmed/20211002 http://dx.doi.org/10.1186/1471-2466-10-11

Ejemplares similares

Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data
por: Bleecker, Eugene R, et al.
Publicado: (2011)

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
por: Vogelmeier, Claus, et al.
Publicado: (2010)

Once-daily indacaterol 75 μg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients’ perceived onset of effect
por: Siler, Thomas M, et al.
Publicado: (2014)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
por: Vincken, Walter, et al.
Publicado: (2014)

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
por: Balint, Beatrix, et al.
Publicado: (2010)

Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2012)

Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist
por: Roig, Jorge, et al.
Publicado: (2009)

Safety of indacaterol in the treatment of patients with COPD
por: Donohue, James F, et al.
Publicado: (2011)

Indacaterol: a new once daily long-acting beta(2) adrenoceptor agonist
por: Beeh, Kai M, et al.
Publicado: (2010)

New developments in the management of COPD: clinical utility of indacaterol 75 μg
por: Steiropoulos, Paschalis, et al.
Publicado: (2013)

A UK-Based Cost-Utility Analysis of Indacaterol, A Once-Daily Maintenance Bronchodilator for Patients with COPD, Using Real World Evidence on Resource Use
por: Price, David, et al.
Publicado: (2013)

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
por: Roskell, Neil S, et al.
Publicado: (2014)

Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study
por: Salomon, Joerg, et al.
Publicado: (2017)

Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial
por: Beasley, Richard W, et al.
Publicado: (2015)

Efficacy, Safety, and Systemic Exposure of Once-Daily Indacaterol Acetate in Pediatric Asthma: A Randomized, Double-Blind, Controlled Dose-Finding Study
por: Sekerel, Bulent Enis, et al.
Publicado: (2023)

Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US
por: Rajagopalan, Krithika, et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women
por: Feldman, Robert A., et al.
Publicado: (2021)

Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review
por: Ulrik, Charlotte Suppli
Publicado: (2014)

Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
por: Mtibaa, Mondher, et al.
Publicado: (2021)

Medication Adherence and Asthma Control with Once-Daily Indacaterol/Glycopyrronium/Mometasone Furoate Breezhaler Digital Companion: 90-Day Analysis from Germany
por: Woehrle, Holger, et al.
Publicado: (2023)

Is once enough? Understanding the preferences of COPD and asthma patients for once- versus twice-daily treatment
por: Horne, Rob
Publicado: (2013)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
por: Buhl, Roland, et al.
Publicado: (2012)

Efficacy and safety of olodaterol once daily delivered via Respimat(®) in patients with GOLD 2–4 COPD: results from two replicate 48-week studies
por: Ferguson, Gary T, et al.
Publicado: (2014)

Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol
por: Beier, Jutta, et al.
Publicado: (2011)

Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
por: Gong, Shiyi, et al.
Publicado: (2021)

Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial
por: Singh, Dave, et al.
Publicado: (2022)

Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease – a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2011)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
Publicado: (2014)

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD
por: D’Urzo, Anthony
Publicado: (2013)

Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study
por: Boye, Kristina, et al.
Publicado: (2020)

Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2012)

How different is the once-weekly teriparatide from the daily one or the same?
por: Takeuchi, Yasuhiro
Publicado: (2019)

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
por: Horita, Nobuyuki, et al.
Publicado: (2015)

A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study
por: Juvelekian, Georges, et al.
Publicado: (2015)

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
por: Ridolo, Erminia, et al.
Publicado: (2019)

Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease
por: Hataji, Osamu, et al.
Publicado: (2013)

The 24-h FEV(1) time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies
por: Feldman, Gregory J, et al.
Publicado: (2014)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019)

Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study
por: Woodcock, Ashley, et al.
Publicado: (2014)

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO
por: Molina, Jean-Michel, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9cuslut0he81vhjqa90jjr8sk8